Invex Therapeutics (ASX:IXC) Beta: 1.2178 (As of Jun. 26, 2026)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
37 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Beta?

Invex Therapeutics ASX:IXC 37 Beta is 1.2178 as of Jun. 26, 2026. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Invex Therapeutics's Beta is 1.2178.


Invex Therapeutics  (ASX:IXC) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Invex Therapeutics Beta Related Terms


Invex Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Beta Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial 0.00 1.82 0.78 1.20 0.92

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.20 0.94 0.92 1.09

ASX:IXC vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Invex Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invex Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Beta falls into.


ASX:IXC
37GF Score
Invex Therapeutics Ltd ASX:IXC
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.2178 mean?
Invex Therapeutics (ASX:IXC) has a Beta of 1.2178 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Beta too high?
Invex Therapeutics' current Beta is 1.2178. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Beta compare to VRTX and REGN?
Invex Therapeutics' Beta of 1.2178 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Beta is 1.2178. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Beta of 1.2178. The current Beta is 1.2178. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Beta is 1.2178 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score

Get the complete analysis for ASX:IXC

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price